Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential gene expression for A2780 human ovarian cancer cells when exposed to a new osmium-based anticancer agent

ABSTRACT: Differential gene expression for A2780 human ovarian cancer cells when exposed to a new osmium-based anticancer agent

PROVIDER: PRJEB14015 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1413440_1.fastq.gz	Fastqsanger.gz
	ERR1413440_2.fastq.gz	Fastqsanger.gz
	ERR1413450_1.fastq.gz	Fastqsanger.gz
	ERR1413450_2.fastq.gz	Fastqsanger.gz
	ERR1413460_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 60

Similar Datasets

Differential gene expression for A2780 human ovarian cancer cells when exposed to a new osmium-based anticancer agent

Project description:Platinum-based metallodrugs are the most widely used anticancer agents. Their reduced effectiveness after repeat dosing (resistance) constitutes a major clinical problem. In this experiment we study a potent organo-osmium compound with improved activity over cisplatin and no cross-resistance in platinum-resistant cancers. A2780 cells were exposed to an osmium anticancer compound and to a negative control solution, in triplicate. At 0, 4, 12, 24 and 48 h, cells were collected for each condition, and whole cell RNA was extracted. Samples were purified and QC checked before Truseq library preparation and Illumina sequencing. Each sample had approximately 30 million paired-end reads. Samples were mapped to the human genome using Tophat2 and differential expression analysed using edgeR.

2016-05-22 | E-MTAB-2758 | biostudies-arrayexpress

RNA seq analysis of A2780 and A2780-ADR

Project description:RNA seq analysis of A2780 and A2780-ADR

| PRJNA736941 | ENA

RNA seq analysis of A2780 and A2780-ADR

Project description:We compared the global RNA expression level between doxorubicin-sensitive human ovarian cancer cell line A2780 and the adriamycin-resistant cell line A2780-ADR to elucidate the drug resistant related molecular mechanisms or targets.

2022-12-09 | GSE177038 | GEO

Drug Resistance-Related Gene Targets and Molecular Mechanisms in the A2780 Paclitaxel-Resistant Cell Line of Epithelial Ovarian Cancer

Project description:To investigate the gene targets associated with paclitaxel resistance in EOC, we cultured A2780 and paclitaxel resistant A2780 (A2780-Taxol) cell lines.

2023-06-01 | GSE230667 | GEO

Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780).

Project description:The effects of Auranofin (AF) on protein expression and protein oxidation in A2780 cancer cells were investigated through a strategy based on simultaneous expression proteomics and redox proteomics determinations. Bioinformatics analysis of the proteomics data supports the view that the most critical cellular changes elicited by AF treatment consist of thioredoxin reductase inhibition, alteration of the cell redox state, impairment of the mitochondrial functions, metabolic changes associated with conversion to a glycolytic phenotype, induction of ER stress. The occurrence of the above cellular changes was extensively validated by performing direct biochemical assays. Our data are consistent with the concept that AF produces its effects through a multitarget mechanism that mainly affects the redox metabolism and the mitochondrial functions and results into severe ER stress. Results are discussed in the context of the current mechanistic knowledge existing on AF.

| S-EPMC8966199 | biostudies-literature

GDF15 is a secretary protein from ovarian cancer cell A2780 and induced by cisplatin in vivo

Project description:A2780 is a cisplatin sensitive ovarian cancer cell line. A2780 ovarian cancer cells was treated with different doses of cisplatin in an attempt to identify biomarkers that can be used to predict chemoresponse. We used microarrays to identify genes induced by cisplatin in a time dependent manner.

2018-11-08 | GSE122287 | GEO

Expression profiling of cisplatin resistant derivatives of ovarian cancer cell line A2780

Project description:The goal of this study was to determine genes with altered expression after selection of ovarian cancer cells for survival in increasing concentrations of cisplatin. A series of progressively cispatin resistant derivatives of A2780 ovarian cancer cell lines was hybridized to spotted cDNA microarrays using two color technology using the parental A2780 cells as a reference. Duplicate hybridizations were carried out for each resistant derivative.

2013-12-22 | E-GEOD-44022 | biostudies-arrayexpress

Comparing control and IL17A treated A2780-derived ovarian cancer stem cell

Project description:A2780-derived ovarian cancer stem cells were in vitro cultured in the presence of 10 ng/mL basic fibroblast growth factor , 20 ng/mL epidermal growth factor , 5 M-NM-<g/mL insulin, 0.4% bovine serum albumin. Then ovarian cancer stem cells were stimulated for 4 and 6 hours in the presence or absence of 250ng/ml IL17A. Total RNA was isolated and processed according to the AgilentmanufacturerM-bM-^@M-^Ys standard protocols Gene expression in ovarian cancer stem cells from A2780 cell line was measured at IL17A stmulated (4 and 6 hours) and un-stmulated.

2012-07-27 | E-GEOD-39698 | biostudies-arrayexpress

Differences in gene expression in A2780C20 vs. A2780

Project description:Differences in gene expression in A2780C20 vs. A2780 and A2780 treated with temsirolimus at 24-hr and 48-hr. The A2780 are human ovarian carcinoma cellls were purchased to the European Collection of Cell Cultures (ECACC). The A2780CP20 are cisplatin resisatnt cells derived of the A2780 cells. A2780CP20 cells were generated by Dr. Robert Ozols (J. Natl. Cancer Inst. 84, 264-267 (1992) by treatment of A2780 cells with incresing concentrations of cisplatin. The goal of this study is to determine whether the cisplatin and temsirolimus resistance are co-regulated. The objectives of this study are to identify additional genes differentially expressed in cisplatin sensitive and cisplatin resistant ovarain cancer cells and the changes in gene expreession upon temsirolimus treatment of A2780 cells.

2013-10-25 | GSE51683 | GEO

Transcription profiling of Rab25 transfected ovarian A2780 cancer cell

Project description:To elucidate potential mechanisms by which Rab25 contributes to tumor aggressiveness, we determined the transcription profile induced by expression of Rab25. Twenty-four independent samples, 12 from pcDNA transfected and 12 from Rab25 expressing A2780 ovarian cancer cells were profiled on Affymetrix GeneChip HT-HG_U133A Early Access Array.

2011-12-30 | E-GEOD-28299 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data